Brazilian Prison Study Shows Ayahuasca Reduced Recidivism Rates Compared to Control Group
"The recidivism rate or the return to prison rate in the ayahuasca-exposed individuals was statistically significantly lower than the recidivism rate in the control group, suggesting that, you know, whatever is going on there seems to have an effect on whatever drives criminal behavior."
About this episode
In this Huberman Lab Essentials episode, host Andrew Huberman interviewed Dr. Nolan Williams, a Stanford psychiatrist and neurologist specializing in treatment-resistant depression and brain stimulation technologies. The conversation centered on revolutionary approaches to treating severe depression, particularly Williams' Stanford Neuromodulation Therapy (SNT), which achieves 60-90% remission rates within 1-5 days by compressing 7.5 months of traditional TMS treatment into an intensive protocol. Williams revealed the American Heart Association recently added depression as the fourth major cardiovascular risk factor alongside hypertension, cholesterol, and diabetes, underscoring depression's systemic health impact. The discussion challenged foundational psychiatric assumptions, with Williams explicitly stating the chemical imbalance theory is false and proposing 'Psychiatry 3.0' focused on correctable brain circuits rather than serotonin deficits or irreversible childhood trauma. Williams presented first-in-human ibogaine research with Navy SEALs and special forces veterans, reporting dramatic resolution of moral injury and PTSD symptoms after 24-36 hour sessions described as 'ten years of psychotherapy in a night.' The conversation covered psilocybin trials showing two-thirds clinical improvement in depression, MDMA's efficacy for PTSD with effects lasting years, and a Brazilian prison study demonstrating ayahuasca reduced recidivism rates. Williams emphasized these substances should never be recreational and require strict medical supervision, positioning psychedelic-assisted therapy as a potential breakthrough combining drug effects with psychotherapeutic processing. Throughout, he stressed the importance of rigorous clinical trials and treating depression as a fixable electrophysiological problem rather than permanent deficiency.
Key takeaways
- Williams' Stanford accelerated TMS protocol achieves 60-90% depression remission within 5 days by delivering 90 minutes of stimulation hourly across 50 total hours.
- First human ibogaine study with special forces veterans shows dramatic relief from moral injury and PTSD after 24-36 hour sessions inducing life review and self-forgiveness.
- American Heart Association recently added depression as the fourth major risk factor for heart disease alongside hypertension, cholesterol, and diabetes.
- Williams explicitly rejected the chemical imbalance theory of depression, stating psychiatry has long known it's false and proposing circuit-based 'Psychiatry 3.0' model.
- Brazilian prison research found ayahuasca sessions statistically reduced recidivism rates compared to control groups, suggesting behavioral change mechanisms.
- Psilocybin trials show two-thirds clinical improvement in treatment-resistant depression, with MDMA demonstrating similar efficacy for PTSD with multi-year durability.
- TMS research demonstrates direct brain-heart connections, with stimulation over mood regions capable of decelerating heart rate and affecting cardiac function.